Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 201–300 of 930
Liu, D.-X., Li, D., He, W., Ke, C., Wu, J., Tang, J.-H., Kong, L.-H., Li, Y., Sui, Q., Xiao, B.-Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1711650 · Cited by 50
Zhang, X., Gari, A., Li, M., Chen, J., Qu, C., Zhang, L., & Chen, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03252-7 · Cited by 49
Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
Kabiljo, J., Harpain, F., Carotta, S., & Bergmann, M. M. (2019) · Cancers · doi:10.3390/cancers12010079 · Cited by 49
“However, recent data from murine xenograft models of a neoadjuvant treatment setting show promising effects of immunotherapy on survival in the latter yet non-metastatic setting [193].”
BackgroundImmunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes
Shalhout, S. Z., Kaufman, H. L., Emerick, K. S., & Miller, D. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2971 · Cited by 48
Lymph nodes: at the intersection of cancer treatment and progression
Reticker-Flynn, N. E., & Engleman, E. G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.04.001 · Cited by 47
T lymphocyte-targeted immune checkpoint modulation in glioma
Kelly, W., Giles, A. J., & Gilbert, M. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000379 · Cited by 51
Kos, K., Salvagno, C., Wellenstein, M. D., Aslam, M. A., Meijer, D. A., Hau, C., Vrijland, K., Kaldenbach, D., Raeven, E. A. M., Schmittnaegel, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2063225 · Cited by 47
Rusch, V. W., Nicholas, A., Patterson, G. A., Waqar, S. N., Toloza, E. M., Haura, E. B., Raz, D. J., Reckamp, K. L., Merritt, R. E., Owen, D. H., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.10.007 · Cited by 47
Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis
Thomas, S. K., Lee, J., & Beatty, G. L. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102662 · Cited by 47
“Indeed, mouse models support a role for neoadjuvant immunotherapy for improved outcomes [87].”
BackgroundPreclinical models and technologies to advance nanovaccine development
Peres, C., Matos, A. I., Moura, L. I. F., Acúrcio, R. C., Carreira, B., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Satchi‐Fainaro, R., & Florindo, H. F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.001 · Cited by 48
Novel adjuvant options for cutaneous melanoma
Dimitriou, F., Long, G. V., & Menzies, A. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.198 · Cited by 52
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1382 · Cited by 47
Xia, H., Zhang, H., Ruan, Z., Zhang, H., Sun, L., Chen, H., Zhou, Y., Zhang, L., Bian, D., Zhu, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01861-w · Cited by 44
“The most common reason for failure to perform surgery was incomplete resectability in both arms (66.7% [10/15] in arm A and 50.0% [6/12] in arm B).”
BackgroundInfluentialThe Future of Perioperative Therapy in Advanced Renal Cell Carcinoma: How Can We Prosper?
Patel, H. D., Puligandla, M., Shuch, B. M., Leibovich, B. C., Kapoor, A., Master, V. A., Drake, C. G., Heng, D. Y., Lara, P. N., Choueiri, T. K., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0951 · Cited by 44
John, A. O., & Ramnath, N. (2023) · The Oncologist · doi:10.1093/oncolo/oyad125 · Cited by 46
Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC
Brockwell, N. K., Rautela, J., Owen, K. L., Gearing, L. J., Deb, S., Harvey, K., Spurling, A., Zanker, D. J., Chan, C., Cumming, H. E., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0093-2 · Cited by 44
“Not only does this work support neoadjuvant therapy for the discovery and development of biomarkers, studies in multiple murine TNBC models have also shown improved outcomes to alternative therapies when therapy is given in the neoadjuvant setting as opposed to adjuvant.(33,34) Despite previous reports showing no safe…”
ResultDeterminants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
“To combat these negative events, ICIs are being explored as neoadjuvant therapies prior to surgery [150].”
BackgroundImmunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results
Liu, N., Wu, J., Deng, E., Zhong, J., Wei, B., Cai, T., Xie, Z., Duan, X., Fu, S., Osei-Hwedieh, D. O., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03873-7 · Cited by 48
Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer
Yeh, J., Marrone, K. A., & Forde, P. M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.109 · Cited by 42
Immunologic and immunogenomic aspects of tumor progression
Ladányi, A., & Tímár, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.011 · Cited by 46
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Etxeberría, I., Bolaños, E., Teijeira, Á., Garasa, S., Yanguas, A., Azpilikueta, A., Kavanaugh, W. M., Vasiljeva, O. S., Belvin, M. P., Howng, B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025930118 · Cited by 42
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
Yavuz, B. G., Hasanov, E., Lee, S. S., Mohamed, Y. I., Curran, M. A., Koay, E. J., Cristini, V., & Kaseb, A. O. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s322289 · Cited by 43
“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
Bell, H. N., Cotta, B. H., Salami, S. S., Kim, H. L., & Vaishampayan, U. N. (2021) · Kidney Cancer · doi:10.3233/kca-210010 · Cited by 42
“In a breast cancer animal model trial neoadjuvant immunotherapy produced a broader array of immune response as compared to the use of same therapy after resection of the primary tumor [17].”
BackgroundCiccarese, C., Strusi, A., Arduini, D., Russo, P., Palermo, G., Foschi, N., Racioppi, M., Tortora, G., & Iacovelli, R. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102528 · Cited by 42
Takahashi, T., Tateishi, A., Bychkov, A., & Fukuoka, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102578 · Cited by 42
“In the murine model of breast cancer, neoadjuvant ICI therapy resulted in a sustained increase of tumor-specific CD8+ T cells in the blood, which predicted long-term survival [18].”
BackgroundAdjuvant Treatment of Melanoma: Recent Developments and Future Perspectives
Testori, A., Ribero, S., Indini, A., & Mandalà, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00456-4 · Cited by 45
Caluwé, A. D., Buisseret, L., Poortmans, P. M., Gestel, D. V., Salgado, R., Sotiriou, C. P., Larsimont, D., Paesmans, M., Craciun, L., Drisis, S., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08601-1 · Cited by 43
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
Friedlaender, A., Naidoo, J., Banna, G. L., Metro, G., Forde, P. M., & Addeo, A. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102350 · Cited by 44
Yang, Y., Tan, L., Hu, J., Li, Y., Mao, Y., Tian, Z., Zhang, B., Ma, J., Li, H., Chen, C., et al. (2022) · Diseases of the Esophagus · doi:10.1093/dote/doac031 · Cited by 43
Self-citationLi, S., Xu, Q., Dai, X., Zhang, X., Huang, M., Huang, K., Shi, D., Wang, J., & Liu, L. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13143-w · Cited by 40
Cao, L., Zhong, N., Chen, Y., Li, Z., Wang, G.-R., Xiao, Y., Liu, X.-H., Jia, J., Liu, B., & Bu, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217095 · Cited by 41
Neoadjuvant PD-1 Inhibitors and Chemotherapy for Locally Advanced NSCLC: A Retrospective Study
Chen, T., Ning, J., Campisi, A., Dell’Amore, A., Ciarrocchi, A. P., Li, Z., Song, L., Huang, J., Yang, Y., Stella, F., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.03.041 · Cited by 40
Xu, J., Yan, C., Li, Z., Cao, Y., Duan, H., & Ke, S. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12752-1 · Cited by 40
Smussi, D., Mattavelli, D., Paderno, A., Gurizzan, C., Lorini, L., Romani, C., Bignotti, E., Grammatica, A., Ravanelli, M., & Bossi, P. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102644 · Cited by 39
The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives
Wisdom, A. J., Barker, C. A., Chang, J. Y., Demaria, S., Formenti, S. C., Grassberger, C., Gregucci, F., Hoppe, B. S., Kirsch, D. G., Marciscano, A. E. E., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.12.046 · Cited by 41
Houda, I., Dickhoff, C., Groot, C. A. U., Reguart, N., Provencio, M., Lévy, A., Dziadziuszko, R., Pompili, C., Maïo, M. D., Thomas, M., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100840 · Cited by 49
Immune Checkpoint Blockade across the Cancer Care Continuum
Helmink, B. A., Gaudreau, P.-O., & Wargo, J. A. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.003 · Cited by 41
Rohaan, M. W., Stahlie, E. H. A., Franke, V., Zijlker, L. P., Wilgenhof, S., van der Noort, V., van Akkooi, A. C. J., & Haanen, J. B. A. G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09896-4 · Cited by 40
Kim, C. G., Hong, M. H., Kim, D., Lee, B. H., Kim, H., Ock, C., Kelly, G., Bang, Y. J., Kim, G., Lee, J. E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3249 · Cited by 38
Marandino, L., Campi, R., Amparore, D., Tippu, Z., Albiges, L. K., Capitanio, U., Giles, R. H., Gillessen, S., Kutikov, A., Larkin, J., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.09.002 · Cited by 41
Chung, C. K., Silva, C. G. D., Kralisch, D., Chan, A. B., OSSENDORP, F. A., & Cruz, L. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.011 · Cited by 41
Reijers, I. L. M., Menzies, A. M., López‐Yurda, M., Versluis, J. M., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115141 · Cited by 38
Is earlier better for melanoma checkpoint blockade?
Robert, C. (2018) · Nature Medicine · doi:10.1038/s41591-018-0250-0 · Cited by 39
Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer
Isaacs, J., & Stinchcombe, T. E. (2022) · Drugs · doi:10.1007/s40265-022-01721-3 · Cited by 41
Aravindan, A., Gupta, A., Moorkoth, S., & Dhas, N. L. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106007 · Cited by 40
Immunotherapy in patients with early stage resectable nonsmall cell lung cancer
Ghysen, K., & Vansteenkiste, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000497 · Cited by 36
PD-1 Blockade in Early-Stage Lung Cancer
Rosner, S., Reuss, J. E., & Forde, P. M. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-025205 · Cited by 39
Shu, C., & Li, Q. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102965 · Cited by 41
Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Soh, J., Hamada, A., Fujino, T., & Mitsudomi, T. (2021) · Cancers · doi:10.3390/cancers13164035 · Cited by 38
Therapeutic Targeting of Tumor-Infiltrating Regulatory T Cells in Breast Cancer
Fattori, S., Roux, H., Connen, E., Robert, L., Gorvel, L., Roy, A. L., Houacine, J., Foussat, A., Chrétien, A.-S., & Olive, D. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0654 · Cited by 37
Fu, Y., Guo, X., Sun, L., Cui, T., Wu, C., Wang, J., Liu, Y., & Liu, L. (2024) · eLife · doi:10.7554/elife.95009 · Cited by 39
“Pilot neoadjuvant studies assessing anti- PD-1 antibodies alone or with anti- CTLA-4 antibodies are also underway ( Pinato et al., 2021 ; Topalian et al., 2020 ; Haber et al., 2021 ; Lee et al., 2015 ; Liu et al., 2016 ).”
BackgroundZhang, Z., Cheng, S., Gong, J., Lu, M. S., Zhou, J., Zhang, X., Li, J., Shen, L., & Peng, Z. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.06.034 · Cited by 36
Zanker, D. J., Spurling, A., Brockwell, N. K., Owen, K. L., Zakhour, J. M., Robinson, T., Duivenvoorden, H. M., Hertzog, P. J., Mullins, S., Wilkinson, R. W., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1177 · Cited by 35
Amin, N., Maroun, C. A., Asmar, M. E., Alkhatib, H. H., Guller, M., Herberg, M. E., Zhu, G., Seiwert, T. Y., Pardoll, D. M., Eisele, D. W., et al. (2021) · Head & Neck · doi:10.1002/hed.26935 · Cited by 35
Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials
Witt, R. G., Erstad, D. J., & Wargo, J. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083052 · Cited by 39
Bagegni, N. A., Davis, A. A., Clifton, K., & Ademuyiwa, F. O. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s293597 · Cited by 39
Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
Kalvapudi, S., Vedire, Y., Yendamuri, S., & Barbi, J. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1286104 · Cited by 35
“Liu et al., demonstrated this effect in a murine model of triple-negative breast cancer (88).”
BackgroundRimini, M., Masi, G., Lonardi, S., Nichetti, F., Pressiani, T., Lavacchi, D., Lucchetti, J., Giordano, G., Scartozzi, M., Tamburini, E., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01060-1 · Cited by 34
Ho, A. Y., Shiao, S. L., Kobald, S. A., Chen, J. H., Duda, D. G., Ly, A., Bossuyt, V., Cho, H. L., Arnold, B. B., Knott, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00003 · Cited by 35
Blair, A. B., & Murphy, A. G. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.10.004 · Cited by 34
Bex, A., Thienen, J. V., Schrier, M., Graafland, N. M., Kuusk, T., Hendricksen, K., Lagerveld, B. W., Zondervan, P. J., van Moorselaar, R. J. A., Blank, C. U., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0111 · Cited by 36
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot
Janjigian, Y. Y., Wolchok, J. D., & Ariyan, C. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.013 · Cited by 36
Welti, M., Dimitriou, F., Gutzmer, R., & Dummer, R. (2022) · Cancers · doi:10.3390/cancers14225489 · Cited by 34
Takada, K., Takamori, S., Brunetti, L., Crucitti, P., & Cortellini, A. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.017 · Cited by 33
Mitsudomi, T., Ito, H., Okada, M., Sugawara, S., Shio, Y., Tomii, K., Okami, J., Sakakura, N., Kubota, K., Takamochi, K., et al. (2023) · Cancer Science · doi:10.1111/cas.16030 · Cited by 33
“3,15,16 Additionally, chemotherapy enhances antitumor immunity through direct or indirect activation of the immune system, providing a rationale for combination strategies with immunotherapy.”
BackgroundRay-Coquard, I. L., Savoye, A.-M., Schiffler, C., Mouret‐Reynier, M., Derbel, O., Kalbacher, E., Leheurteur, M., Martínez, A., Cornila, C., Martinez, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46999-x · Cited by 33
Principles of Immunotherapy in Non-Small Cell Lung Cancer
Hsu, M. L., & Naidoo, J. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.009 · Cited by 36
Kim, H.-S., Jeong, B. C., Hong, J., Kwon, G. Y., Kim, C. K., Park, W., Pyo, H., Song, W., Sung, H. H., Hong, J. Y., et al. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.343 · Cited by 33
Yip, W., Ghoreifi, A., Gerald, T., Lee, R. A., Howard, J. M., Asghar, A. M., Khanna, A., Cai, J., Aron, M., Gill, I. S., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.03.003 · Cited by 33
Hieken, T. J., Nelson, G. D., Flotte, T. J., Grewal, E. P., Chen, J., McWilliams, R. R., Kottschade, L. A., Yang, L., Domingo‐Musibay, E., Dronca, R. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45798-8 · Cited by 33
Immunotherapy in Triple-Negative Breast Cancer: Present and Future
Kim, I., Sanchez, K. G., McArthur, H. L., & Page, D. B. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00345-z · Cited by 34
Seizing the fate of lymph nodes in immunotherapy: To preserve or not?
Xu, Z., Li, Z., Cao, L., Zhong, N., Liu, X.-H., Wang, G.-R., Xiao, Y., Liu, B., & Bu, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216740 · Cited by 32
Immunotherapy in colorectal cancer
Agarwal, P., Le, D. T., & Boland, P. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.002 · Cited by 35
Antimetastatic defense by CD8+ T cells
de Lara, P. T., Castañón, H., Sterpi, M., & van den Broek, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.006 · Cited by 33
Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
Petričević, B., Kabiljo, J., Zirnbauer, R., Walczak, H., Laengle, J., & Bergmann, M. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.015 · Cited by 32
Ahern, E. S., Cubitt, A., Ballard, E. L., Teng, M. W. L., Dougall, W. C., Smyth, M. J., Godbolt, D., Naidoo, R., Goldrick, A., & Hughes, B. G. M. (2019) · Trials · doi:10.1186/s13063-019-3951-x · Cited by 33
Self-citationAdjuvant treatment for locally advanced gastric cancer: an Asian perspective
Kim, H., Ryu, M., & Kang, Y. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01484-8 · Cited by 31
“As neo-adjuvant ICI treatment has additional benefits of maximizing tumor-specific T cell responses to prevent recurrence than adjuvant ICI treatment [60, 61], it will be of interest to see if there is an impact of adding ICI to neoadjuvant vs. adjuvant chemotherapy in patients with LAGC.”
Keung, E. Z.-Y., & Gershenwald, J. E. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa012 · Cited by 42
Lü, Y., Ng, A. H. C., Chow, F. E., Everson, R. G., Helmink, B. A., Tetzlaff, M. T., Thakur, R., Wargo, J. A., Cloughesy, T. F., Prins, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24293-4 · Cited by 30
Guan, Y., Feng, D., Yin, B., Li, K., & Wang, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221096877 · Cited by 30
Milling, L. E., Garafola, D., Agarwal, Y., Wu, S., Thomas, A., Donahue, N. D., Adams, J., Thai, N., Suh, H., & Irvine, D. J. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0247 · Cited by 18
“Previous studies using the 4T1model ofmetastatic breast cancer theorized that survival benefit in the neoadjuvant setting may be limited to therapies that invoke antitumor T-cell responses (31).”
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Boydell, E., Sandoval, J. L., Michielin, O. A., Obéid, M., Addeo, A., & Friedlaender, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411849 · Cited by 33
“It has also been suggested that necrosis of the primary tumour may lead to an increased shedding of tumour-specific antigens and, therefore, have the potential to induce systemic priming and the expansion of antigen-presenting cells [4].”
BackgroundNeoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
Chen, Y., Yan, B., Xu, F., Hui, Z., Zhao, G., Liu, J., Zhang, H., Zeng, Z., Zhang, R., Provencio, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-329 · Cited by 30
Self-citationDixon-Douglas, J. R., Loibl, S., Denkert, C., Telli, M. L., & Loi, S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351186 · Cited by 31
Neoadjuvant Therapy for Hepatocellular Carcinoma
Zongyi, Y., Chen, D., Liang, S., & Li, X. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s357313 · Cited by 31
Deslypere, G., Gullentops, D., Wauters, E., & Vansteenkiste, J. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918772810 · Cited by 29
An integrated framework for the study of exercise across the postdiagnosis cancer continuum
Courneya, K. S., McNeely, M. L., Booth, C. M., & Friedenreich, C. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1432899 · Cited by 28
Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions
Sadrinasab, S., Saket, S., Pourmohammadi, N., Khosravi, F., & Fakhr, M. S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02773-z · Cited by 30
Immuno-Oncology for Esophageal Cancer
Yamamoto, S., & Kato, K. (2020) · Future Oncology · doi:10.2217/fon-2020-0545 · Cited by 31
Koumarianou, A. A., & Durán, J. (2021) · Cancers · doi:10.3390/cancers13030363 · Cited by 35
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
Tang, Q., Zhao, S., Zhou, N., He, J., Zu, L., Liu, T., Song, Z., Chen, J., Peng, L., & Xu, S. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5497 · Cited by 32
“Therefore, neoadjuvant immunotherapy may decrease the risk of disease recurrence and benefit the OS of patients with cancer (15).”
BackgroundInfluentialYang, R., Wu, T., Yu, J., Cai, X., Li, G., Li, X., Huang, W., Zhang, Y., Wang, Y., Yang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182299 · Cited by 29
“Median (range) 55 (23–74) 44(23-69) 55(43-62)”
Neoadjuvant therapy of locally/regionally advanced melanoma
Khunger, A., Buchwald, Z. S., Lowe, M., Khan, M. K., Delman, K. A., & Tarhini, A. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919866959 · Cited by 29
Neoepitopes-based vaccines: challenges and perspectives
Alcazer, V., Bonaventura, P., Tonon, L., Valsesia‐Wittmann, S., Caux, C., & Depil, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.011 · Cited by 30
Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies
Pignot, G., Loriot, Y., Kamat, A. M., Shariat, S. F., & Plimack, E. R. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.01.002 · Cited by 28
FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction
Liu, S., Wang, H., Li, J., Zhang, J., Wu, J., Li, Y., Piao, Y., Pan, L., Xiang, R., & Yue, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03004-9 · Cited by 29
Immunodynamics of explanted human tumors for immuno‐oncology
Dubuisson, A., Fahrner, J., Goubet, A., Terrisse, S. A., Voisin, N., Bayard, C., Lofek, S., Drubay, D., Bredel, D., Mouraud, S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012850 · Cited by 28
Zhang, F., Qiu, B., Ji, Y., Guo, W., Li, N., Xue, Q., Gao, S., & He, J. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1007 · Cited by 27
Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
Cao, C. Q., Le, A., Bott, M. J., Yang, C. J., Gossot, D., Melfi, F. M. A., Tian, D. H., & Guo, A. (2021) · Current Oncology · doi:10.3390/curroncol28060395 · Cited by 28
Zhao, X., Kassaye, B., Wangmo, D., Lou, E., & Subramanian, S. (2020) · iScience · doi:10.1016/j.isci.2020.101056 · Cited by 29
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.